Chondroitin at pharmacokinetic effects in the plasma concentration of rivaroxaban

Chondroitin at pharmacokinetic effects in the plasma concentration of rivaroxaban were dose dependent. The rapid absorption allows it to reach maximum inhibition of FXa activity within 1 to 4 hours after oral administration. The inhibition of FXa activity was found to range from 20% to 61% for the 5 to 80 mg doses.6 The standard dose of rivaroxaban has an oral bioavailability of 80% to 100%.7 It has a negligible interaction with diet. Thus, food restrictions are not necessary. In addition, rivaroxaban has no significant drug accumulation after its steady state. The area under the plasma concentration time curve and C increase slightly after the administration of 40 mg rivaroxaban compared with 30 mg, but no further chemical screening accumulation after administration of 50 mg rivaroxaban.8 In terms of drug distribution, plasma protein binding is very high, almost 95% in vitro. Rivaroxaban is not expected to be dialyzable since it has very high plasma protein binding. The human plasma to blood partition coefficient is 1.40. The volume distribution at steady state is approximately 50 L, resulting in low tissue affinity.9 Rivaroxaban is mainly metabolized by cytochrome P450 isoforms, particularly CYP3A4.
Therefore, several drug interactions are important to recognize, including ketonazole and ritonavir, which are major rhein inhibitors of CYP3A4. Rivaroxaban should be used cautiously if these potent CYP3A4 inhibitors are concomitantly used.4 Rivaroxaban has a dual mode of elimination. Two third is metabolized by the liver to inactive metabolites and one third is excreted in urine by kidneys in unchanged forms.4 These elimination processes result in an average half life of 7 to 11 hours.8 There are special considerations in some population groups. In patients with mild, moderate, and severe renal impairment, AUC increases by 44%, 52%, and 64%, respectively. Meanwhile, in patients with mild hepatic impairment, the AUC increased by 15%, and in patients with moderate hepatic impairment it increased by 127%. In summary, caution should be taken for patients with any level of renal impairment and/or liver impairment.9 Pharmacodynamics ZD6474 Rivaroxaban is a competitive and a direct inhibitor of serine protease coagulation FXa. Factor Xa is activated by both the extrinsic and intrinsic coagulation cascades, which exerts a crucial role in the coagulation pathway.
Factor Xa converts prothrombin to thrombin, and, finally, this complex process results in the formation of fibrin clot and activation of platelets by thrombin. The pharmacodynamic investigations demonstrated the evidence of a dose dependent inhibition of FXa generated by rivaroxaban. The correlation between concentration and effect was well pronounced for the prothrombin time, followed by the activated partial thromboplastin time. Thus, PT may be used as a marker for anticoagulation effect of rivaroxaban. However, the association between PT and activity of rivaroxaban is poor. The relationship between PT and bleeding complications has been investigated in phase III studies which revealed the PT threshold was not accurately predicted bleeding complications in a use of rivaroxaban. In addition, rivaroxaban has no effect on thrombin content in plasma and did not interact with antithrombin.10 Interaction studies of pharmacodynamics.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>